Ashling Wahner

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.

Key Takeaways Competing-risk analyses demonstrated persistent escalation in second-line therapy probability, supporting frontline selection that anticipates longitudinal sequencing in patients aged ≥75 years with CLL/SLL. Age stratification revealed higher second-line use in 75–79 versus ≥80 years, likely influenced by shorter follow-up and competing mortality in older strata. Absence of del(17p)/TP53 testing correlated with higher next-treatment incidence than documented biomarker groups, underscoring real-world gaps in risk stratification and treatment planning. BTK inhibitor monotherapy became the predominant frontline approach after 2014, replacing rituximab monotherapy; Richter transformation was uncommon (1.7%) despite high mortality (52.3%). SHOW MORE

Highlights From BGB-16673 Phase 1 Drug Interaction Studies In a human absorption, metabolism, and excretion study, fecal excretion accounted

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Key Takeaways European first-line approval targets metastatic TNBC patients naive to metastatic systemic therapy who cannot receive PD-(L)1 inhibitors, expanding use of a TROP2-directed ADC earlier in care. ASCENT-03 randomized 1:1 to sacituzumab govitecan 10 mg/kg days 1/8 q21d versus physician's-choice chemotherapy, with crossover to second-line sacituzumab govitecan after BICR-confirmed progression. Blinded central review showed clinically meaningful PFS improvement (9.7 vs 6.9 months; HR 0.62), with concordant investigator-assessed PFS (9.6 vs 6.8 months; HR 0.64). Objective response rates were comparable, yet sacituzumab govitecan produced longer responses (median DOR 12.2 vs 7.2 months) and maintained patient-reported physical functioning through week 25. Prespecified biomarker analyses demonstrated PFS benefit across BRCA status, HER2 IHC subgroups, and TROP2 expression quartiles, supporting broad activity without a restrictive biomarker threshold. SHOW MORE

Key Takeaways China's approval positions iza-bren as the first globally approved bispecific ADC, targeting EGFR and HER3 via a brengitecan-based ADC platform in heavily pretreated NPC. Phase 3 PANKU-NPC01 showed superior BICR-confirmed ORR (54.6% vs 27.0%; OR 3.3) and improved DOR and PFS versus capecitabine/gemcitabine/docetaxel. Eligibility required progression after PD-1/PD-L1 therapy and ≥2 prior chemotherapy lines including platinum, ECOG 0–1, and adequate life expectancy, in a China-based open-label randomized design. Safety favored chemotherapy, with more grade ≥3 TRAEs (79.9% vs 61.6%), more serious TRAEs (43.4% vs 27.0%), frequent dose modifications, and four treatment-related deaths on iza-bren. Hematologic toxicities were more common with iza-bren; ILD occurred at grade 2 in two patients on iza-bren, while grade 3 ILD occurred in two patients receiving chemotherapy. SHOW MORE